Company intelligence / Profile preview

Shenzhen Superbio Technology

Shenzhen, Guangdong, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Superbio has FDA clearance (2023) for the first portable point-of-care device detecting fentanyl in urine (RYAN™/EASY-11); products commercialized in the US via Bioeasy USA and Carolina Liquid Chemistries Corp.; pipeline includes rapid tests for drugs of abuse and infectious diseases

Therapeutic areas: CardiovascularOtherInfectious DiseasesPulmonology
Modalities: DeviceImmunoassay
Industry: Protein Biomarker Diagnostics

Partnerships

Bioeasy USACarolina Liquid Chemistries Corp.

Beyond the preview

Go deeper on Shenzhen Superbio Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Superbio Technology.

Explore the full profile